LOUISVILLE, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX), a leader in lung disease diagnostic solutions, will release its third-quarter financial results before trading starts on Friday, November 1, 2024. A conference call and webcast to discuss the results will be held at 8:30 a.m. Eastern Time on the same day.
Listeners can register for the webcast via the provided link. Analysts wishing to participate in the Q&A session should use another designated link. A replay of the webcast will be available on the company’s investor website about two hours after the call ends. Attendees should join 15 minutes early.
About Biodesix
Biodesix offers five Medicare-covered tests for lung diseases. Their Nodify Lung® Nodule Risk Assessment helps doctors assess the cancer risk in lung nodules. The IQLung™ tests support treatment decisions for lung cancer patients at all stages. Biodesix also partners with top biopharmaceutical companies for biomarker discovery and diagnostic development. Visit biodesix.com for more information.
Note on Forward-Looking Statements
This press release includes forward-looking statements subject to risks and uncertainties as per the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and could differ from actual results due to various factors. For details on risks, see Biodesix’s latest Form 10-K annual report filed on March 1, 2024.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20241018266313/en/
Media Contact:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investor Contact:
Chris Brinzey
chris.brinzey@westwicke.com
(339) 970-2843
Source: Biodesix, Inc.
`
